Icometrix developers brain imaging technology based on KU Leuven and University of Antwerp research to help assess conditions such as Alzheimer’s disease.
Icometrix, a Belgium-based brain imaging technology spinout of Katholieke Universiteit (KU) Leuven and University of Antwerp, has obtained $18m in a round co-led by Forestay Capital, Optum Ventures and Capricorn Venture Partners.
Forestay Capital is a subsidiary of investment group Waypoint Capital, which has assisted Icometrix with elements of its technical strategy in Europe.
Founded in 2011, Icometrix has created a software platform called Icobrain that supports the evaluation of MRI and CT brain scans to diagnose neurological disorders including multiple sclerosis (MS), Alzheimer’s disease and traumatic brain injury.
The software, sanctioned as safe in the US, Europe and other key markets, uses artificial intelligence technology to automatically segment visual data and compare the patient to healthy subjects in a given demographic.
Icometrix currently markets three products based on the approach, catered to MS, dementia and traumatic brain injuries.
The spinout received more than $2.2m in a 2016 round featuring KU Leuven, University of Antwerp and Antwerp University Hospital, as well as Capricorn’s ICT Arkiv fund and Annie Vereecken, investing on behalf of investment vehicle Biover II.
Private investor Herman Verrelst also participated in the round alongside unspecified additional investors.
